Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

被引：0
|
作者：
Baglioni, Piero [1 ]
机构：
[1] Ctr Hosp St Jean DAngely, St Jean Dangely, France
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 377卷 / 21期
关键词：
SITAGLIPTIN; MELLITUS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：2097 / 2098
页数：2
相关论文
共 50 条
  • [21] Canagliflozin approved for type 2 diabetes
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 834 - 834
  • [22] Canagliflozin: A Review in Type 2 Diabetes
    Emma D. Deeks
    André J. Scheen
    Drugs, 2017, 77 : 1577 - 1592
  • [23] CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES
    Babu, A.
    DRUGS OF TODAY, 2013, 49 (06) : 363 - 376
  • [24] Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results
    Weir, Matthew R.
    McCullough, Peter A.
    Buse, John B.
    Anderson, John
    AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (04) : 276 - 288
  • [25] Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes
    Ragot, Stephanie
    Saulnier, Pierre-Jean
    Velho, Gilberto
    Gand, Elise
    de Hauteclocque, Astrid
    Slaoui, Yousri
    Potier, Louis
    Sosner, Philippe
    Halimi, Jean-Michel
    Zaoui, Philippe
    Rigalleau, Vincent
    Fumeron, Frederic
    Roussel, Ronan
    Marre, Michel
    Hadjadj, Samy
    DIABETES CARE, 2016, 39 (07) : 1259 - 1266
  • [26] Albuminuria and Renal Function as Risk Factors for Cardiovascular Events and Mortality in Patients With Type 2 Diabetes
    Eliasson, Bjorn
    Cederholm, Jan
    Zethelius, Bjorn
    Gudbjornsdottir, Soffia
    Svensson, Maria K.
    DIABETES, 2012, 61 : A360 - A360
  • [27] PromarkerD Predicts Late-Stage Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
    Peters, Kirsten E.
    Di Prinzio, Patsy
    Bringans, Scott
    Davis, Wendy A.
    Davis, Timothy
    Lipscombe, Richard J.
    Hansen, Michael K.
    DIABETES, 2022, 71
  • [28] Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
    Baksh, Sheriza N.
    Segal, Jodi B.
    McAdams-DeMarco, Mara
    Kalyani, Rita R.
    Alexander, G. Caleb
    Ehrhardt, Stephan
    PLOS ONE, 2020, 15 (10):
  • [29] Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Based on History of Cardiovascular Disease or Cardiovascular Risk Factors
    Davies, Michael J.
    Merton, Katherine
    Vijapurkar, Ujjwala
    Yee, Jacqueline
    Qiu, Rong
    CIRCULATION, 2016, 134
  • [30] EFFICACY AND SAFETY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES BASED ON HISTORY OF CARDIOVASCULAR DISEASE OR CARDIOVASCULAR RISK FACTORS
    Davies, Michael J.
    Merton, Katherine
    Vijapurkar, Ujjwala
    Cuffee, Maurice
    Yee, Jacqueline
    Qiu, Rong
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S176 - S176
12345